Posted by Michael Wonder on 26 Nov 2019
ICER releases evidence report on JAK inhibitors to treat rheumatoid arthritis
26 November 2019 - Using adalimumab as the comparator, upadacitinib’s value-based price benchmark is between $44,000-$45,000 per year; at December 9 public meeting, experts will also review the already high prices of adalimumab and other treatments when discussing what constitutes fair pricing for this class of drugs.
The Institute for Clinical and Economic Review today released an Evidence Report assessing the comparative clinical effectiveness and economic value of JAK inhibitors for treating rheumatoid arthritis.
These therapies include upadacitinib (Rinvoq, AbbVie), tofacitinib (Xeljanz, Pfizer), and baricitinib (Olumiant, Eli Lilly).
